Global Vaccine & Biologics Commercialization, Merck Manufacturing Division, Merck & Co., Inc. West Point, PA 19486, United States.
Downstream Process Development, GlaxoSmithKline, King of Prussia, PA 19406, United States.
Curr Opin Biotechnol. 2018 Oct;53:144-150. doi: 10.1016/j.copbio.2018.01.004. Epub 2018 Feb 3.
Chinese hamster ovary (CHO) cells are the most prevalent host organism for production of recombinant therapeutic proteins, including monoclonal antibodies (mAbs). Regulatory guidance mandates control of the host cell protein (HCP) concentration in the production process, which remains a primary challenge. Although HCP concentrations are typically measured by ELISA, orthogonal proteomic methods are gaining popularity for identification and quantitation of individual HCP species. Recent applications of proteomic techniques to characterize extracellular CHO HCPs include those that have explored the effects of upstream factors (cell line, viability, process conditions), characterized specific HCPs likely to co-purify by mAb interactions, identified HCPs likely to impact drug product quality, and enabled strategies to limit HCP expression (media composition, temperature shift, genetic modification) and maximize clearance (polishing chromatography, wash additives).
中国仓鼠卵巢(CHO)细胞是生产重组治疗性蛋白(包括单克隆抗体)最常用的宿主生物。监管指南要求控制生产过程中的宿主细胞蛋白(HCP)浓度,这仍然是一个主要挑战。尽管 HCP 浓度通常通过 ELISA 进行测量,但正交蛋白质组学方法越来越受欢迎,用于鉴定和定量个别 HCP 物种。最近将蛋白质组学技术应用于表征细胞外 CHO HCP 的应用包括:探索上游因素(细胞系、活力、工艺条件)的影响、鉴定可能通过 mAb 相互作用共纯化的特定 HCP、鉴定可能影响药物产品质量的 HCP 以及确定限制 HCP 表达(培养基成分、温度骤变、遗传修饰)和最大限度地清除 HCP(抛光色谱、添加洗脱剂)的策略。